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Neurokinin A, Not Bradykinin, Cause the ACE
Inhibitor induced Cough
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Baseline L
SinusCL 1041 * 169 873k 123”’
AH intetval 115*43 99*20**
AVN ERP 388+ 124 325&74”
AtrfslERP 24Sk 25 225 l24**
Ventr.ERP 251 k 17 246*22*”
APD (50%) 233* 25 242 +25**
APD (90%) 276 &27 283&31ns
QT (V5) 358* 26 365+25ns
**p<0.01,*p <0.05, ns = p >0.05 comparedto baaeline
Thus L in acute administration facilitates impulse formation and conduc-
tion in alow reaponae tissue, enhances recovery of excitability in working
heart muacle, and may delay ventricular repolarizstion. A likely mechanism
is phosphodieaterese Ill inhibition, an ancillary property acting at higher con-
centrations of the drug. In conclusion, L hae a potential to influence cardiac
rhythm on various struefursl levels of the heart.
n919 Risk Factors for Atherosclerosis
Sunday,March16, 1997,5:00p.m.-7:OOp.m.
AnaheimConventionCenter,HallE
PresentationHour:5:00p.m.–7:OOp.m.
a91958 FibrinogenisanIndependentRickFactorforCoronaryHeartDiseaseinWomen:Reportfrom
theStockholmStudyinWomen
M. Erfkaeonl, K. Schenck-Guatafsson1, N. Egberg1, K. Orth-Gom6r1,
M.A. Mittleman2. 1Kam/inskaHospital,Kam/inskaInstitute,Stockholm,
Sweden,2DeeconaasHospital,Boston,USA
The role of fibrinogen in female coronary heart diaease (CHD) is unclear.
We examined the ability of plasma fibrinogen to predict CHD in a population-
based case-control study of women aged 65 yeare or younger, living in the
greater Stockholm area. Cases were all patients hospitalized for an acute
CHD event between Feb. 1991 and Feb. 1994. Controls were randomly
selected from the city census and were matched to eases by age and
cstchment area. Fibrinogen was measured 3t06 monthsafter hospitalization,
IJelnga fibrinogen polymerization time assay. Or the 292 consecutive cases,
110 (37%) suffered from an acute myocardial infarction and 1S2(63%) from
angina pactoris. The mean age in both cases and controls was 56 + 7
years (range 30-65 yeara). Seventy-four (25%) cases and 64 (29%) controls
were premenopauaal and 36 (12?4.)cases and 40 (14%) controls were using
hormone replacement therapy (HRT). Mean levels of fibrinogen in cases and
controls were3.67 + 0.61 g/Land 3.25 +0.64 g/L, respectively(p < 0.0001).
Age-adjusted odda ratio for CHD in the highest versus the lowest quartile of
fibrinogen was 6.01 (95% Cl. 3.46, 10.39). Adjusting for age, smoking, total
cholesterol, LDL, HDL, triglycerides, systolic blood pressura, waist-hip ratio
and education, the odds ratio was 2.95 (95% Cl. 1.59, 5.47). In pre- and
poatmenopaueal woman the multivariate adjusted odds ratiowere6.74 (95%
Cl. 1.74, 26.11) and 2.14 (95% Cl. 1.03, 4.44), respectively. No difference
in these results was obtained when adjusting for HRT.
Conclusion:These results suggest that fibrinogen is an independent risk
factor for CHD in women and it seems to be a stronger risk factor in the
younger age group. This is in concordance with less atheromatosis and
stenosis on coronaty angiograme in this group indicating that thrombogenesis
is more impottsnt than atherogenesis in younger women.
~19-59)T.morNecr05i5Fa~or-~and,nsu,in,n.rsa*
PlaamlnogenActivatorInhibitor-1Productionin
Adipocytes
T. Sakamoto, J. Woodcock-Mitchell, K. Marutsuka, B.E. Sobel, S. Fujii.
Universityof Vermont,Burlington,VT USA
Adipose tisaues of obese human subjeets express elevated Ievela of tumor
necrosis factor (TNF)-u. We have previously shown that TNF-o isa key madi-
atorof pmduetion of plasminogen activator inhibitor-1 (PAI-1),the physiologic
inhibitor of fibrinolyais, in adipocytes. To determine the moleeular mecha-
nism(s) bywhich TNF-a induces PAI-I production, 3T3LI preadipocyfeswere
differentiated into adipocytes by dexamethasone (0.25 MM) and isobutylx-
anthine (0.5 mM), and stimulated by TNF-u (0.6-10 rig/ml) for 24 h; cell
conditioned medium was assayed for PAI-I by Western blot. TNF-a (5 rig/ml)
selectively increased the syntheais of PAI-I (2.6 + 0.4 fold) (mean + SD) (n
= 6); t-PA and u-PA Ievele remained unchanged. The increase in PAI-1 was
deteeted at 6 h with maximal ascretion at 24 h. PAI-1 secretion was inhib-
ited by cycloheximide (25 #g/ml, n =9) implying new protein syntheais. The
hydroxyl radical scavenger tetramethylthiourea (20 mM) completely abol-
ished the TNFw induced increase in PAI-1 (n = 6). Superoxide (generatsd
by xanthine oxidase 10 mU/ml plus hypoxanthine 0.6 mM), and hydrogen
peroxide (100 ~M) were potent inducer of PAI-I (n= 6). Chronic exposure of
adipocytes to TNF-a (5 rig/ml) over 5 days under the preeencs of insulin (20
nM) aleo increased PAI-1 production (3.1 + 0.5 fold) (n = 6). The interaction
of insulin and TNF-cxto PAI-1 production of adipocytes proved to be syner-
gistic by using of Barenbaum’s isobolic/hyperplane mathematical model (R
value <0.7). These results suggest that (1) adipocytes can generste reactive
oxygen species independently of infiltrating cells, which act as autacoids
and acutely induce PAI-I; (2) chronic interference by TNF-a with the aignal-
ing of insulin through ite receptor consequently stimulates PAI-I production
of adipocytes. This induction may contribute to fibrinolytic dysfunction and
thrombosis in obese patiente with insulin resietsnce.
-[ Th~Aug~sn~ationof~n~othelia,~e,,~.Pr ssion
of PlasminogenActivatorInhibitorType1 (PAI-1)
byInsulinisMediatedbya FactorReleasedby
VascularSmoothMuscleCells
D,J. Schneider, M.A. Ricci, P.M.Absher. Universityof Vermopt,Burlington,
Vermont,USA
Ineulin resistant states such as type II diabetes are characterized by ac-
celerated atherosclerosis and increased concentrations in blood of insulin
and PAI-I. In order to define direet effects of insulin on arterial expression
of PAI-I, we characterized the response of human and porcine arterial tis-
sue maintained in organ culture in response to insulin and compared these
results to those of specific arterial wall constituents maintained in culture
independently and together (co-culture). Accumulation of PAI-1 (by ELISA)
in 24 hr conditioned media increased when human and porcine arteriee were
exposed to insulin (fold induction: [1 nM insulin/control] human = 2.1 + 0.2,
p <0.001, porcine 1.7 + 0.2, p < 0.01). Insulin did not alter accumulation
of PAI-I in media conditioned by endothelial cells (EC) or smooth muscle
cells (SMC) in independent culture but augmented accumulation of PAI-I
was observed in 24-hour conditioned media when EC were co-cultured with
SMC (fold induction: human = 1.6 * 0.1, p = 0.02, porcine = 2.7 4=0.3, p
< 0.01). This effect was reproduced when EC, cultured independently, were
exposed to 24-hour media conditioned by SMC in the presence of insulin.
The size of this soluble factor is greater than 30,000 (MW) ae determined by
reproduction of the effect following fractionation by ultrafiltration. Accordingly,
the increaeed PAI-I in the blood of subjects with type II diabetes appears to
be attributable, in part, to augmented arterial elaboration of PAI-I induced by
a factor released by vascular smooth muacle cells that is induced by insulin.
1919-651EffetiSOfHOrmOne~heraPYonFibrino,fii~
Potentialin PostmenopausalWomen
K.K. Koh, R. Mincem.oyer,M.N. Bui, G. Csako, F. Pucino, R.O. Cannon Ill.
NHLBI,N/H,Bethesda,MD,USA
Plasminogen activator inhibitor (PAI-1), plasma levels of which tise in women
following menopause, may be of pathogenetic importance in acute coronary
syndromes by inhibiting fibrinolysis on vascular surfacee. Beeause oxidized
low-density lipoprotein (LDLox) and lipoprotein(a) [(Lp(a))] promote the syn-
thesis and release of PAI-1 in endothelial cell culture, we examined the effect
of conjugated estrogen (CE) 0.625 mg daily with and without medroxypro-
gesterone acetate (MPA) 2.5 mg daily on PAI-1 and Lp(a) plasma levels,
and LDLox in 30 postmenopausal women in a randomized, crossover study.
Therapies were given for 1 month following baeeline meaaurements, with
a 1 month washout period between treatments. Time to onset of copper-
catalyzed oxidation of LDL from these women was assayed by specfropho-
tometry. CE reduced PA1-1-from31 +34 to 14 + 10 ng/mL (p c 0.001) (data
= mean + SD), and Lp(a) from 29.9 + 22.5 to 26.7 + 20.2 mg/dL (p= 0.07).
CE+MPA reduced PAI-I from 31 + 29to 15 + 11ng/mL (P= O.001),and Lp(a)
from 32.2 + 22.6 to 25.6 + 16.1 mg/dL (p = 0.02). Neither therapy alterad
LDLox. There was no correlation between treatment changes in PAI-I levels
and changes in LDLox or in Ievele of aatrone, estradiol, LDL cholesterol,
high-density lipoprotein cholesterol, or Lp(a). Thus, CE and CE+MPA aimi-
Iarly reduce PAI-I levels by approximately 50% in postmenopausal women,
independent of factors that stimulate endothelial release of PAI-1, suggesting
inhibition of non-endothelial (e.g., hepatic) sources of PAI-I.
